<DOC>
	<DOCNO>NCT00656175</DOCNO>
	<brief_summary>Ritonavir-boosted protease inhibitor ( PI ) regimens become backbone treatment people HIV . However , adverse drug effect , particularly lipodystrophy/lipoatrophy closely associate regimen . Therefore , need drug comparable effectiveness ritonavir boost PIs without side effect dyslipidemia , associate elevate cholesterol cardiovascular disease Raltegravir HIV integrase inhibitor phase III clinical development . To date approve drug target stage HIV-1 lifecycle . However , data study indicate raltegravir generally safe well tolerate strong antiretroviral activity use combination license antiretroviral medication . This study aim demonstrate patient substitute raltegravir PI NNRTI base antiretroviral regimen associate 10 % reduction body fat 24 week . The study consist total 10 subject visit period 48 week . Approximately 40 female patient participate study ( approximately 10 UCLA ) .</brief_summary>
	<brief_title>Raltegravir Therapy Women With HIV Fat Accumulation</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 infection document licensed ELISA test kit confirm Western blot time prior study entry plasma HIV1 RNA &gt; 2000 two occasion , Female subject 18 year older Documented central fat accumulation ( defined waist circumference &gt; 94 cm waist hip ratio &gt; 0.88 ) . Documented HIV RNA &lt; 50 copies/mL screen &lt; 400 copies/mL past 6 month . Current antiretroviral therapy two nucleoside analogue either nonnucleoside analogue ( nevirapine , efavirenz TMC125 ) approve protease inhibitor . Patients NNRTI+PI study entry exclude . Study participant need first regimen . No change ART 12 week prior screen . The nucleoside backbone must include either tenofovir abacavir either lamivudine emtricitabine . Fixed dose combination emtricitabine abacavir allow . For female reproductive potential ( woman postmenopausal least 24 consecutive month , i.e. , menses within precede 24 month , woman undergo surgical sterilization , specifically hysterectomy , bilateral oophorectomy and/or tubal ligation ) , need negative serum urine pregnancy test within 48 hour prior entry . Ability willingness subject provide inform consent . Pregnancy : current within past 6 month breast feed Prior treatment history would preclude use emtricitabine abacavir nucleoside backbone study treatment Current use metformin thiazolidinediones . Use growth hormone growth hormone release factor last 6 month screen . Change initiation antihyperlipemic regimen within 3 month prior randomization ; Use stable antihyperlipemic regimen study allow . Current use androgen therapy . Intent modify diet , exercise habit enroll weight loss intervention study period . Current project need use rifampin , dilantin phenobarbital 48week study period . Laboratory value screen ANC &gt; 500 cells/mm3 Hemoglobin &lt; 10 gm/dl CrCl &gt; 60 ml/min ( estimate CockcroftGault equation ) AST ALT &gt; 3 x ULN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>lipodystrophy</keyword>
	<keyword>fat</keyword>
	<keyword>visceral fat</keyword>
	<keyword>HIV</keyword>
	<keyword>woman</keyword>
	<keyword>raltegravir</keyword>
	<keyword>ART</keyword>
	<keyword>anti HIV therapy</keyword>
	<keyword>NNRTI</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>treatment experience</keyword>
</DOC>